JHL Biotech Installs GE Healthcare's FlexFactory Biomanufacturing Platform - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

JHL Biotech Installs GE Healthcare's FlexFactory Biomanufacturing Platform


GE Healthcare has completed installation of its FlexFactory biomanufacturing platform at JHL Biotech’s Research Center and manufacturing plant in Hsinchu, Taiwan, the companies announced in a press release. The new manufacturing platform will follow cGMPs and be fully operational by the end of 2013. It is similar to the production process at JHL Biotech’s KUBio modular biopharmaceutical factory currently under construction by GE Healthcare in Wuhan, China.

GE Healthcare’s FlexFactory is a centrally automated, flexible biomanufacturing platform. It allows manufacturers to quickly and easily establish biopharmaceutical manufacturing capacity within an existing building or as part of a new facility, which allows manufacturers to rapidly respond to local healthcare needs. FlexFactory is comprised of single-use technologies and associated process hardware as well as all necessary automation and control components for start-to-finish manufacturing of biopharmaceuticals.

JHL Biotech’s FlexFactory in Taiwan will be used for cell line development, process development, and cGMP manufacturing in preclinical and early-stage clinical work.  In addition, it will serve as a proving ground for JHL Biotech for technology transfer. GE Healthcare’s Shanghai Fast Trak team will validate equipment at the site and will train local JHL Biotech staff. JHL Biotech’s facility includes two 500L single-use bioreactors, with the option to expand to four if greater throughput is required. FlexFactory enables JHL Biotech to develop manufacturing processes prior to launching full-scale manufacturing operations in its Taiwan facility and prior to its KUBio factory in Wuhan becoming fully operational in early 2015. 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here